Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
個股明細
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
INKT
MiNK Therapeutics, Inc.
NASDAQCM
Biotechnology
United States
$11.64
▲
+0.32 (+2.83%)
CLOSED
—
OPEN
$11.16
HIGH
$11.64
AT HIGH
LOW
$11.18
PREV CLOSE
$11.32
VOLUME
5.7K
0.40x avg
BID / ASK
8.31 / 14.59
spr 6.280
MARKET CAP
$59.4M
DAY RANGE
$11.18
$11.64
P/E (TTM)
—
Fwd -4.4
EPS (TTM)
-2.37
DIV YIELD
—
52W HIGH
$16.98
-31.4%
52W LOW
$8.48
+37.3%
BETA
0.49
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$11.41
-0.23
(-1.98%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
INKT
$11.64
▲
+2.83%
Chart
Valuation
Financials
Peers
News
INKT · K 線技術分析（即時、可互動）
basic
pro
快速分析（約半分鐘，最長 5 分鐘）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，通常約半分鐘，上游壅塞時最長 5 分鐘。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
一年走勢
RISK-OFF
252 BARS · -21.4% YOY
1-year price chart. Started at 14.80, currently 11.64, down 21.4 percent. Range 8.56 to 16.30 over 252 data points.
2025-09-05
$14.80 → $11.64 (-21.4%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Recent News
Loading § Recent News
編輯內容 · 非投資建議。
資料來源：Finnhub（報價 / 公司資料 / 新聞 / 同業）＋ Yahoo（統計）＋ SEC EDGAR XBRL（財務 + DCF）。伺服器端數值經 ISR 快取，最長 60 分鐘；報價則在你的瀏覽器裡即時更新。
VALUATION
確定性估值（SEC EDGAR + Finnhub）
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
—
WACC Used
+7.0%
Terminal g
+3.5%
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers. · Comparables skipped: no peer multiples or no per-share economics from Finnhub metric endpoint.
FINANCIALS
多年財務（SEC XBRL）
—
3 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$12.5M
-$5.9M
—
$14.2M
2024-12
—
-$10.8M
-$9.6M
—
$5.7M
2023-12
—
-$22.5M
-$15.8M
-$15.8M
$4.6M
NEWS
近期新聞（過去 14 天）
CALM
8 HEADLINES · LAST 14 DAYS
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript
Motley Fool · 2026-08-14
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 2026-08-14
MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...
GuruFocus.com · 2026-08-13
MiNK Therapeutics Q2 Earnings Call Highlights
MarketBeat · 2026-08-13
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
GlobeNewswire · 2026-08-13
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
GlobeNewswire · 2026-08-06
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
GlobeNewswire · 2026-08-06
Here's Why You Should Add INKT Stock to Your Portfolio Now
Zacks · 2026-07-16